Scientific Report 2003-2004 - Cleveland Clinic Lerner Research ...

More documents

Recommendations

Info

THE DANESHGARILABORATORYPOSTDOCTORAL FELLOWGuiming Liu, M.D., Ph.D.The Department of Cancer BiologyBladder Disease in Diabetes Arises fromChanges in Tissue, Accumulation ofAdvanced Glycosylation EndproductsSENIOR RESEARCH TECHNOLOGISTLateef Saffore, M.S.COLLABORATORSC. Thomas Powell, Ph.D. 1Frank Bockowitz, M.D., Ph.D. 21Dept. of Cancer Biology, CCF2Dept. of Physiology, CaseWestern Reserve Univ.,<strong>Cleveland</strong>, OHThe main focus of our laboratory is onbladder physiology and the pathophysiologyof bladder diseases. The initial modelof bladder pathology being investigated in ourlaboratory is diabetes mellitus.Up to 83% of the patients with eitherinsulin-dependent (type 1) or noninsulindependent(type 2) diabetes suffer fromcomplications in the lower urinary tract. Thesecomplications are manifestedas voiding dysfunction,evidenced by increasedbladder capacity withdecreased contractility, andinfection, evidenced byrecurrent and complicatedinfections.The traditional view onthe pathophysiology ofvoiding dysfunction indiabetic cystopathy has beenthat it arises from autonomicneuropathy. Based onaccumulated data from theliterature and from ourlaboratory, our alternativehypothesis is that the mainpathologic condition indiabetic cystopathy arises fromchanges occurring underhyperglycemic conditions inthe bladder tissue itself. Basedon this hypothesis, theaccumulation of advanced glycosylationendproducts (AGEs) could cause alterations inthe phenotype of diabetic bladder and impairedcontractility of the bladder.Our laboratory has shown that, in theimpaired contractility caused by diabetes,alterations in the translocation and temporaldistribution of certain isoenzymes of proteinkinase C (PKC) occur, with a marked change inDaneshgari, F. (2001) Valsalva leak point pressure: steps toward standardization. Curr.Urol. Rep. 2:388-391.Lee, R.S., DeAntoni, E., and F. Daneshgari (2002) Compliance with recommendationsof the urodynamic society for standards of efficacy for evaluation of treatmentoutcomes in urinary incontinence. Neurourol. Urodyn. 21:482-485.Daneshgari, F., Washington, M., Babekir, N., El-Azab, A., Hoogwerf, B., Barber, M.,Rackley, R., and S. Vasavada (2002) Lower urinary tract complications of diabetesmellitus in adult population: A cross sectional study. International Continence SocietyAnnual Meeting. Germany, September 2002.Daneshgari, F., Saffore, L., and S. Choudhary (2002) Temporal profile of proteinkinase C isozymes in the urothelium and Detrusor of rat. 22 nd Annual meeting ofAmerican Urogynecological Society. San Francisco, October 2002.Daneshgari, F., Wyne, K., Ferruchi, P., and S. Choudhary (2002) Animal models ofdiabetes for studies of lower urinary tract complications. J. Urol. (submitted).Firouz Daneshgari, M.D.isoenzyme BII, in particular. Our current effortfocuses on the effects of the accumulation ofAGEs on PKC function in bladder tissue.During 2002, we started translation of theabove work to clinical investigation. WithInstitutional Review Board approval, we havestarted recruiting patients with diabetes into twoparallel clinical studies. In one study, the prevalenceof diabetic complication is assessed byseveral questionnaires,uroflowmetry and post-voidresidual. The patients withevidence of diabeticcystopathy undergo multichannelurodynamic studies,cystoscopy and biopsy oftheir bladder. Contractilitystudies and identification ofPKC isozymes and AGEs aresubsequently performed. Inthe other arm of the study, asample of bladder ofpatients with end-stagediabetes who undergo renaltransplantation is obtained.Similar samples fromoutpatient patients,contractility studies andidentification of PKCisozymes and AGEs areperformed. The dataemerging from thesetranslational studies are veryencouraging.A very exciting development in ourlaboratory during 2002 was an invitation (via aU01 supplement grant from the National Instituteof Diabetes and Digestive and Kidney Diseases)to Dr. Daneshgari to join the Animal Models ofDiabetes Consortium of NIH as the chair of asubcommittee to characterize diabetic uropathy.The aim of this consortium is to create animalmodels of diabetes by varioius knock-out andtransgene technologies.During 2002, the work in our laboratorywas recognized by two awards: a Young InvestigatorAward of the National Kidney Foundationand a Grant-in-Aid from the Diabetes Associationof the Greater <strong>Cleveland</strong>, awarded to Dr.Daneshgari in July.52
The Department of Cancer BiologyEnteric Pathogen RegulatesNF-κB Activationof Inflammatory AgentsPathogenic stimulation of the nuclearfactor-κB transcription factor (NF-κB)family of proteins leads to the activationof numerous proinflammatory agents. Expressionof cytokines, chemokines, cellular adhesionproteins and immunoreceptor genes that arerequired for inflammation is dysregulated innearly all cases of chronic and debilitatingdiseases. In our laboratory, we contend thatpathogens are responsible for disrupted signaltransduction pathways, which result in errantimmune response gene expression.Our hypothesis states that pathogenicstimuli commandeer and use normal cellularsignal transduction pathways. Those pathogensusurp the normal control points in the flow ofinformation from the extracellular environmentand the cell membrane to the nucleus.Dysregulated gene expression of inflammatorymediators results in aberrant expression ofinflammatory response genes.Intestinal epithelial cells serve as our modelsystem. We are studying the regulation of the NFκBtranscription factor in response to invasion ofthese cells by pathogenic enteric bacteria. We areusing a variety of biochemical and reverse genetictechniques to precisely interfere with discretesteps in the activation pathway(s) used byproinflammatory cytokines. We are comparinghow this interference affects the signalingpathways activated by the pathogens.Identification of key control nodes alongthe pathogenic signaling pathways will aid in thedevelopment of pharmaceutical compounds thatcan block pathogenic signaling but leave the cell’snormal signal transduction pathways largelyunaffected. Such pharmaceuticals will beextremely useful in the treatment of manychronic inflammatory diseases, such as inflammatorybowel disease, rheumatoid arthritis andnumerous autoimmune and neurodegenerativediseases. Recently, we have identified a patternrecognition receptor on intestinal epithelial cellsthat recognizes bacterial flagellin protein. Therecognition of flagellin by Toll-like receptor 5leads (TLR5) to NF-κB activation and proinflammatorygene expression. Current projectsin the laboratory focus on understanding themolecular interactions and signaling properties ofTLR5 and other TLR family members and theirrelationship to inflammation. Recently, with Dr.Amiya K. Banerjee’s laboratory in CCF’s Sectionof Virology, we have identified a TLR-mediatedpathway of NF-κB activation that recognizesproteins from the medically important humanparainfluenza virus (HPIV3). HPIV3 is a majorcause of lung-related morbidity and disease innewborns, young infants and immunologicallysuppressed individuals. Activation of NF-κB viathis pathway causes the virus to be mildlycytotoxic, whereas blocking the activation ofNF-κB turns the virus infection into a virulentone. In addition, this pathway identifies a novelNF-κB-mediated anti-viral innate host defensesystem.Additional projects in the laboratory focuson identifying structural features of the I-κBkinase (IKK) protein complex that are associatedwith its inactive and active states. IKK is thecentral regulator of NF-κB activation in cells inresponse to a wide variety of cell stimuli. Otherstudies are designed to identify amino acidresidues within the IKK complex that are triggerpoints for IKK activation by other upstreamkinases. Once the structural features of theactive IKK complex and identification of keyactivation amino acid residues and upstreamkinases have been identified, they will serve asexcellent potential drug targets for therapeuticintervention.THE DIDONATOLABORATORYPROJECT SCIENTISTLouis Liou, Ph.D., M.D.Urological Inst., CCFRESEARCH ASSOCIATETing Shi, Ph.D.POSTDOCTORAL FELLOWSNiladri Kar, Ph.D.Thomas Tallant, Ph.D.Provash Sadhukhan, Ph.D.GRADUATE STUDENTJoseph Lupica, B.A.Joseph A. DiDonato, Ph.D.DiDonato, J.A., Hayakawa, M., Rothwarf, D.M., Zandi, E., and M. Karin (1997) A cytokine-responsive IκBkinase that activates the transcription factor NF-κB. Nature 388:548-554.Zamanian-Daryoush, M., Mogensen, T.H., DiDonato, J.A., and B.R. Williams (2000) NF-κB activation bydouble-stranded-RNA-activated protein kinase (PKR) is mediated through NF-κB-inducing kinase and IκBkinase. Molec. Cell. Biol. 20:1278-1290.Purcell, N.H., Yu, C., He, D., Xiang, J., Paran, N., DiDonato, J.A., Yamaoka, S., Shaul, Y., and A. Lin(2001) Activation of NF-κB by hepatitis B virus X protein through an IκB kinase-independent mechanism.Am. J. Physiol. Gastrointest. Liver Physiol. 280:G669-G677.DiDonato, J.A. (2001) IKK alpha on center stage. Science STKE [Electronic Resource: Signal TransductionKnowledge Environment]. 2001(97):PE1.Rani, M.R., Asthagiri, A.R., Singh, A., Sizemore, N., Sathe, S.S., Li, X., DiDonato, J.D., Stark, G.R., andR.M. Ransohoff (2001) A role for NF-κB in the induction of β-R1 by interferon-β. J. Biol. Chem.276:44365-44368.53
Page 7 and 8: From the Chairman, Board of Governo
Page 9 and 10: Continued from Page 6sources. The p
Page 11 and 12: Continued from Page 8initiative rec
Page 13 and 14: BiomedicalEngineering
Page 15 and 16: The Department of Biomedical Engine
Page 21 and 22: Examples of devices that are being
Page 33 and 34: Deep brain stimulation (DBS) of the
Page 36 and 37: ORTHOPAEDICBIOLOGY ANDBIOENGINEERIN
Page 42 and 43: CONNECTIVETISSUEBIOLOGYTHE MIDURALA
Page 46 and 47: DEPARTMENT OFCANCER BIOLOGYCHAIRMAN
Page 48 and 49: The Department of Cancer Biology46D
Page 50 and 51: THE ALMASANLABORATORYVISITING SCHOL
Page 52 and 53: Graham Casey, Ph.D.THE CASEYLABORAT
Page 56 and 57: THE ERZURUMLABORATORYRESEARCH ASSOC
Page 58 and 59: THE HESTONLABORATORYSTAFF SCIENTIST
Page 60 and 61: The Department of Cancer BiologyIde
Page 62 and 63: THE SIZEMORELABORATORYRESEARCH FELL
Page 64 and 65: THE WILLIAMSLABORATORYPROJECT SCIEN
Page 66 and 67: THE YI LABORATORYPOSTDOCTORAL FELLO
Page 68 and 69: DEPARTMENT OFCELL BIOLOGYINTERIM CH
Page 70 and 71: The Department of Cell BiologyRole
Page 72 and 73: THE CHISOLMLABORATORYRESEARCH ASSOC
Page 74 and 75: THE DRISCOLLLABORATORYPOSTDOCTORAL
Page 76 and 77: THE HAZENLABORATORYRESEARCH ASSOCIA
Page 78 and 79: The Department of Cell BiologyHyper
Page 80 and 81: The Department of Cell BiologyRole
Page 82 and 83: THE J. SMITHLABORATORYTECHNOLOGISTG
Page 84 and 85: THE WEIMBSLABORATORYPROJECT SCIENTI
Page 86 and 87: The Department of Cell BiologyCell
Page 88 and 89: DEPARTMENTOF IMMUNOLOGYCHAIRMANThom
Page 90 and 91: THE ARONICALABORATORYSENIOR RESEARC
Page 92 and 93: THE FAIRCHILDLABORATORYPOSTDOCTORAL
Page 94 and 95: THE HAMILTONLABORATORYPROJECT SCIEN
Page 96 and 97: THE LARNERLABORATORYPOSTDOCTORAL FE
Page 98 and 99: THE M. SIEMIONOWLABORATORYRESEARCH
Page 100 and 101: The Department of ImmunologyHyaluro
Page 102 and 103: The Department of ImmunologyImmunol
Page 104 and 105:
DEPARTMENT OFMOLECULAR BIOLOGYCHAIR
Page 106 and 107:
THE GUDKOVLABORATORYPROJECT SCIENTI
Page 108 and 109:
THE HARTERLABORATORYPOSTDOCTORAL FE
Page 110 and 111:
THE PADGETTLABORATORYPROJECT SCIENT
Page 112 and 113:
THE G. SENLABORATORYPROJECT SCIENTI
Page 114 and 115:
THE STARKLABORATORYPROJECT SCIENTIS
Page 116 and 117:
THE PELLETTLABORATORYRESEARCH ASSOC
Page 118 and 119:
The Department of Molecular Biology
Page 120 and 121:
DEPARTMENT OFMOLECULARCARDIOLOGYThe
Page 122 and 123:
THE BERKNERLABORATORYPOSTDOCTORAL F
Page 124 and 125:
THE J. FOXLABORATORYPROJECT SCIENTI
Page 126 and 127:
THE KARNIKLABORATORYRESEARCH ASSOCI
Page 128 and 129:
THE MORAVECLABORATORYRESEARCH SCHOL
Page 130 and 131:
THE PLOWLABORATORYCOLLABORATORSTati
Page 132 and 133:
THE S. SENLABORATORYPOSTDOCTORAL FE
Page 134 and 135:
The Department of Molecular Cardiol
Page 136 and 137:
DEPARTMENT OFNEUROSCIENCESCHAIRMANB
Page 138 and 139:
THE BOULISLABORATORYPOSTDOCTORAL FE
Page 140 and 141:
THE KOMUROLABORATORYCOLLABORATORSAr
Page 142 and 143:
THE MACKLINLABORATORYPROJECT STAFFT
Page 144 and 145:
THE NAJMLABORATORYCOLLABORATORSWill
Page 146 and 147:
THE PERINLABORATORYPOSTDOCTORAL FEL
Page 148 and 149:
THE RANSOHOFFLABORATORYThe Departme
Page 150 and 151:
THE STAUGAITISLABORATORYCOLLABORATO
Page 152 and 153:
THE TRAPPLABORATORYINVESTIGATORSAns
Page 154 and 155:
CENTER FORANESTHESIOLOGYRESEARCHDIR
Page 156 and 157:
Role of Receptors and Ion Channels
Page 158 and 159:
CENTER FORCEREBROVASCULASRESEARCHCe
Page 160 and 161:
THE JANIGROLABORATORYPROJECT SCIENT
Page 162 and 163:
THE HOLLYFIELDLABORATORYPROJECT SCI
Page 164 and 165:
THE ANAND-APTELABORATORYPOSTDOCTORA
Page 166 and 167:
THE HAGSTROMLABORATORYSENIOR TECHNO
Page 168 and 169:
THE V. PEREZLABORATORYTECHNOLOGISTA
Page 170 and 171:
Continued from Page 167active train
Page 172 and 173:
J.J. JACOBS CENTERFOR THROMBOSIS AN
Page 174 and 175:
THE BORDENLABORATORYRESEARCH ASSOCI
Page 176 and 177:
CLEVELAND CENTERFOR STRUCTURALBIOLO
Page 178 and 179:
THE QIN LABORATORYPOSTDOCTORAL FELL
Page 180 and 181:
The view from the skyway between th
Page 182 and 183:
OFFICE OFSPONSORED RESEARCHEXECUTIV
Page 184 and 185:
BIOLOGICAL RESOURCES UNITThe Clevel
Page 186 and 187:
IMAGING COREIMAGING COREDIRECTORJud
Page 188 and 189:
HYBRIDOMA COREHYBRIDOMA COREDIRECTO
Page 190 and 191:
LERNER RESEARCHINSTITUTECOMPUTING S
Page 192 and 193:
ELECTRONICS COREELECTRONICS COREMAN
Page 194 and 195:
MEDICAL SCIENTIFIC COMMUNICATIONSME
Page 196 and 197:
Keyword IndexACESen, I. 129Acoustic
Page 198 and 199:
Keyword IndexMacrophagesHamilton 92
Page 200 and 201:
Illustrations LegendsBIOMEDICAL ENG
Page 202:
Continued from Page 199SCIENTIFIC S
show all

Scientific Report 2003-2004 - Cleveland Clinic Lerner Research ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?